Clinical Trials Logo

Computer Vision Syndrome clinical trials

View clinical trials related to Computer Vision Syndrome.

Filter by:

NCT ID: NCT06163989 Not yet recruiting - Dry Eye Syndromes Clinical Trials

Protecting the Eyes of Gamers With Lubricating Eyedrops

PROTEGE
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The excessive use of screens particularly amongst digital gamers can adversely impact the health of the surface of the eyes with symptoms and signs of surface damage. While strategies including limiting screen time exist, these may be ineffective given the widespread rise of digital device use and gaming culture in the modern era. There is limited evidence for the protective effect of lubricating eyedrops on the ocular surface for handheld console and computer gamers. The aim of this study is to investigate the protective effect of a lubricating eyedrop (TheaLoz Duo) on the surface of the eyes in handheld console and computer gamers. The main question it aims to answer is whether TheaLoz Duo could protect the surface of the eyes from dessication and alleviate symptoms of dry eye disease in handheld console and computer gamers. Participants will receive either the lubricating eyedrop first for 1 month, followed by control saline eyedrop solution for another month, or the other way round. Participants will attend 3 visits in total, each separated by 1 month apart. During each visit, routine clinical assessments of the front of the eye will be conducted. Subsequent findings from this timely study will help improve care of the surface of the eyes for a growing population of gamers worldwide.

NCT ID: NCT06106347 Recruiting - Clinical trials for Computer Vision Syndrome

Analysis of Visual and Ocular Outcomes of Computer Vision Syndrome

Start date: October 15, 2023
Phase:
Study type: Observational

The digital technology is universal and has spread worldwide; thus, digital behaviour has dramatically changed peoples' lifestyles. Previous studies have reported that individuals interact with digital screens for up to 12 hours daily,1,2 and the American Optometric Association defined a combination of ocular and extraocular symptoms that affects the screen users as computer vision syndrome (CVS).3 However, our current understanding of digital technology and its harmful impact on the eye and public health,1,4,5 visual performance,6-8 sleep patterns,7,8 circadian rhythms,5,8 musculoskeletal system activities,3,4 and underlying physiological mechanisms9 remains incomplete and is associated with misconceptions.1 Therefore, educational programs that include protective measures and health campaigns are necessary.10 Computer vision syndrome (CVS) is also called with other names as digital eye strain (DES),3 occupational asthenopia, digital asthenopia,1 and video display terminal syndrome (VDTS). CVS ocular symptoms include visual blur with an underlying mechanism that is not fully understood,10 dry eye disease (DED),3 eye redness and irritation, eyestrain, fatigue, discomfort, difficulty in refocusing the eyes, and diplopia.3,4. CVS extraocular symptoms include headache, sleep disturbances, depression,7,8 musculoskeletal aches, such as neck/shoulder/back pain, difficulty in writing or holding objects, pain in thumbs, fingers, or wrists because of tendonitis and/or arthritis. Smartphones are used extensively worldwide by people of all ages, and have close-viewing distance, related high-definition resolution, thousands of time-consuming applications and games in stores, and 24/7 Internet connectivity. The decline in visual acuity observed in CVS can be attributed to the screen-induced foveal dysfunction11-13 which is a phenomenon that has been extensively documented in the literature using multifocal electroretinogram (mfERG) examinations. Previous studies11-13 consistently reported the presence of this dysfunction, which has been linked to prolonged exposure to digital screens emitting blue light. Notably, recent research has demonstrated noteworthy improvements in foveal responses following a strict reduction in screen time for duration of four weeks.13 These improvements were found to correspond with enhanced visual performances, indicating a positive relationship between the reversal of screen-induced foveal dysfunction and visual outcomes. These findings highlight the reversible nature of screen-induced foveal dysfunction and its potential impact on visual acuity. They support the notion that reducing screen time can serve as an effective intervention strategy, leading to substantial improvements in both foveal responses and overall visual performance.13 The computer vision syndrome questionnaire (CVS-Q) is a self-administered scale that evaluates the frequency and intensity of 16 ocular and visual symptoms related to the use of digital devices. The scoring of the questionnaire follows the procedure of the original version. The 16 items (CVS-symptoms) are scored with two rating scales: one for frequency (never, occasionally, often, or always), and one for intensity (moderate, intense). The responses to the two rating scales for each item are combined multiplicatively into a single scale called symptom severity, and the result should be recoded as 0 = 0; 1 or 2 = 1; 4 = 2. If the total score is ≥ 6 points, the worker is considered to suffer computer vision syndrome .14 Ocular surface disease index is a quick self-assessment questionnaire of the symptoms of ocular irritation in dry eye disease (DED) and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effect it has on vision-related function in the past week of the patient's life.15 The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to "none of the time" and 4 corresponding to "all of the time." A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.15 DED, also known as keratoconjunctivitis sicca, is the condition of having dry eyes. Symptoms include dryness in the eye, irritation, redness, discharge, blurred vision, and easily fatigued eyes. Symptoms range from mild and occasional to severe and continuous. DED can lead to blurred vision, instability of the tear film, increased risk of damage to the ocular surface such as scaring of the cornea, and changes in the eye including the neurosensory system.16

NCT ID: NCT05699057 Completed - Clinical trials for Computer Vision Syndrome

Tendency to Suicide as a Sequel of Computer Vision Syndrome

Start date: October 30, 2022
Phase:
Study type: Observational

CVS-F4 questionnaire will be used as an instrument to survey prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents

NCT ID: NCT05545878 Recruiting - Clinical trials for Computer Vision Syndrome

Impact of 'SESL01' Lens on Computer Vision Syndrome

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The increased use of digital devices such as computers, smart-phones, tablets, and laptops has transformed how people learn and work and has increased the use of screens. This has created visual challenges for some users, such as maintaining a clear vision for a long period even when looking at different devices. Consequently, digital device users can experience eye problems such as blurred vision, eye strain, headaches, and dry eyes. Such problems are more common in people aged 21-45, and it seems that the COVID-19 pandemic has worsened them. Studies suggest that using specially designed lenses could reduce these problems. Therefore, the investigators aim to study whether specially designed lenses are more effective than standard ones in minimising these problems. The study will be conducted at the University of Central Lancashire at the Preston campus (UK). The study will recruit 300 participants, divided into two equal groups. Participants in group A will receive spectacles with special lenses while group B will receive spectacles with standard lenses. All Participants will be assessed three times, at 4-week intervals, and the final analysis will be performed at 14 weeks. The reduction of the eye problems will be assessed using a validated questionnaire which will produce a score that will be compared between the two groups at the end of the study. The study's potential benefits are twofold: 1. Patients using the new lenses will hopefully see a reduction in eye problems 2. Opticians will provide be able to provide better patient care.

NCT ID: NCT05414799 Recruiting - Neck Pain Clinical Trials

Effect of Exercises on Computer Vision Syndrome

Start date: May 11, 2022
Phase: N/A
Study type: Interventional

Computer vision syndrome characterized as a complex of eye and vision problem related with activities which increase stress for close to vision. It includes a group of visual symptoms which occur from the extended viewing of the digital screen, when the demands of the task exceed the abilities of the viewer. Computer vision syndrome is an umbrella term that envelops many eye and environment-related problem that happen when the viewing need of the task increase the visual capability of the computer user which cause inefficacy to focus appropriately on computer images. Computer vision syndrome is also known as Digital Eye Strain.

NCT ID: NCT05211063 Completed - Sleep Disorder Clinical Trials

Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders

Start date: October 21, 2022
Phase: N/A
Study type: Interventional

Previous research has shown the efficacy of CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to evaluate the efficacy of CROCUVIS® in computer vision syndrome, sleep and mood disorders in a sample of university students who use digital devices.

NCT ID: NCT05187221 Completed - Clinical trials for Computer Vision Syndrome

Prevalence and Sequelae of Computer Vision Syndrome in Egyptian Universities

Start date: December 30, 2021
Phase:
Study type: Observational

CVS-F4 questionnaire will be used as an instrument to survey CVS prevalence and severity among medical students

NCT ID: NCT05151302 Completed - Clinical trials for Computer Vision Syndrome

The Italian Version of the Computer-Vision Symptom Scale Questionnaire: Translation, Validation and Reliability.

Start date: February 11, 2015
Phase: N/A
Study type: Interventional

Video display terminal users frequently refer computer-related visual and ocular symptoms, that are the most frequently occurring health problems among such these subjects. The Italian law has established an eye examination to assess ocular status (D.Lgs 81/08 ex law 626/96) in VDT workers: subjects are evaluated by clinical signs and symptoms. The availability of a validated questionnaire could be very useful to diagnose visual disturbances and to follow them during follow-up examinations in 2014, a Spanish group has developed and validated a questionnaire for the assessment of visual and ocular symptoms in VDT workers. Aim of the present study is to make available to Italian health professionals a new instrument to assess asthenopic symptoms, taking into account the patient's perspective.

NCT ID: NCT05087563 Terminated - Clinical trials for Convergence Insufficiency

Neurolens Convergence Insufficiency Study

Start date: November 22, 2021
Phase: N/A
Study type: Interventional

To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Convergence Insufficiency. It is a Prospective randomized double masked two arm performed on a minimum of 100 to a maximum of 150 subjects identified as symptomatic (CISS questionnaire score equal to or greater than 16) done across 3-10 clinical sites. There are two subgroups: a minimum of 50 in each subgroup(subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects(41-60 years).

NCT ID: NCT05070767 Completed - Headache Clinical Trials

Neurolens Headache Study

Start date: October 18, 2021
Phase: N/A
Study type: Interventional

To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Chronic Headaches. It is a Prospective randomized double masked two arm performed on a minimum of 200 to a maximum of 300 subjects identified as symptomatic (HIT-6 questionnaire score equal to or greater than 56) done across 3-15 clinical sites. There are two subgroups: a minimum of 100 in each subgroup (subgroup 1: pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects (41-60 years).